Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer.

Humans Female Neoadjuvant Therapy / methods Immunophenotyping Middle Aged Breast Neoplasms / drug therapy Adult Aged Receptor, ErbB-2 / metabolism Antineoplastic Combined Chemotherapy Protocols / therapeutic use Leukocytes, Mononuclear / metabolism Biomarkers, Tumor / blood Prognosis Lymphocytes, Tumor-Infiltrating / immunology Triple Negative Breast Neoplasms / drug therapy Prospective Studies Treatment Outcome Chemotherapy, Adjuvant / methods

Biomarkers Breast cancer Chemotherapy Immunology Single cell technologies Translational research

Journal

Breast cancer research : BCR

ISSN: 1465-542X

Titre abrégé: Breast Cancer Res

Pays: England

ID NLM: 100927353

Informations de publication

Date de publication:
10 Jun 2024

Historique:

received: 22 02 2024

accepted: 22 05 2024

medline: 11 6 2024

pubmed: 11 6 2024

entrez: 10 6 2024

Statut: epublish

Résumé

Tumor immune infiltration and peripheral blood immune signatures have prognostic and predictive value in breast cancer. Whether distinct peripheral blood immune phenotypes are associated with response to neoadjuvant chemotherapy (NAC) remains understudied. Peripheral blood mononuclear cells from 126 breast cancer patients enrolled in a prospective clinical trial (NCT02022202) were analyzed using Cytometry by time-of-flight with a panel of 29 immune cell surface protein markers. Kruskal-Wallis tests or Wilcoxon rank-sum tests were used to evaluate differences in immune cell subpopulations according to breast cancer subtype and response to NAC. There were 122 evaluable samples: 47 (38.5%) from patients with hormone receptor-positive, 39 (32%) triple-negative (TNBC), and 36 (29.5%) HER2-positive breast cancer. The relative abundances of pre-treatment peripheral blood T, B, myeloid, NK, and unclassified cells did not differ according to breast cancer subtype. In TNBC, higher pre-treatment myeloid cells were associated with lower pathologic complete response (pCR) rates. In hormone receptor-positive breast cancer, lower pre-treatment CD8 + naïve and CD4 + effector memory cells re-expressing CD45RA (T Pre-treatment peripheral blood immune cell populations (myeloid in TNBC; CD8 + naïve T cells and CD4 + T NCT02022202 . Registered 20 December 2013.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

Peripheral blood mononuclear cells from 126 breast cancer patients enrolled in a prospective clinical trial (NCT02022202) were analyzed using Cytometry by time-of-flight with a panel of 29 immune cell surface protein markers. Kruskal-Wallis tests or Wilcoxon rank-sum tests were used to evaluate differences in immune cell subpopulations according to breast cancer subtype and response to NAC.

RESULTS RESULTS

There were 122 evaluable samples: 47 (38.5%) from patients with hormone receptor-positive, 39 (32%) triple-negative (TNBC), and 36 (29.5%) HER2-positive breast cancer. The relative abundances of pre-treatment peripheral blood T, B, myeloid, NK, and unclassified cells did not differ according to breast cancer subtype. In TNBC, higher pre-treatment myeloid cells were associated with lower pathologic complete response (pCR) rates. In hormone receptor-positive breast cancer, lower pre-treatment CD8 + naïve and CD4 + effector memory cells re-expressing CD45RA (T

CONCLUSIONS CONCLUSIONS

Pre-treatment peripheral blood immune cell populations (myeloid in TNBC; CD8 + naïve T cells and CD4 + T

TRIAL REGISTRATION BACKGROUND

NCT02022202 . Registered 20 December 2013.

Identifiants

DOI: 10.1186/s13058-024-01848-z PMID: 38858721

pubmed: 38858721

doi: 10.1186/s13058-024-01848-z

pii: 10.1186/s13058-024-01848-z

doi:

Substances chimiques

Receptor, ErbB-2 EC 2.7.10.1

Biomarkers, Tumor 0

ERBB2 protein, human EC 2.7.10.1

Banques de données

ClinicalTrials.gov

['NCT02022202']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

Subventions

Organisme : NCATS NIH HHS

ID : CTSA Grant Number KL2 TR002379

Pays : United States

Organisme : Mayo Clinic Breast Cancer Specialized Program of Research Excellence Grant

ID : P50CA 116201

Organisme : Mayo Clinic Cancer Center Support Grant

ID : P30 CA15083-40A2

Organisme : Pharmacogenomics Research Network

ID : U19 GM61388

Informations de copyright

Références

Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544–50. https://doi.org/10.1093/annonc/mdu112[publishedOnlineFirst:20140307] .

doi: 10.1093/annonc/mdu112[publishedOnlineFirst:20140307] pubmed: 24608200

Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–7. https://doi.org/10.1200/JCO.2011.41.0902[publishedOnlineFirst:20130122] .

doi: 10.1200/JCO.2011.41.0902[publishedOnlineFirst:20130122] pubmed: 23341518

Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. https://doi.org/10.1016/s1470-2045(17)30904-x[publishedOnlineFirst:2017/12/14] .

doi: 10.1016/s1470-2045(17)30904-x[publishedOnlineFirst:2017/12/14] pubmed: 29233559

Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959.

pubmed: 25071121 pmcid: 4162494 doi: 10.1200/JCO.2013.55.0491

Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37(7):559–69. https://doi.org/10.1200/jco.18.01010[publishedOnlineFirst:2019/01/17] .

doi: 10.1200/jco.18.01010[publishedOnlineFirst:2019/01/17] pubmed: 30650045 pmcid: 7010425

Leon-Ferre RA, Polley M-Y, Liu H, et al. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat. 2018;167(1):89–99.

pubmed: 28913760 doi: 10.1007/s10549-017-4499-7

Leon-Ferre RA, Jonas SF, Salgado R, et al. Tumor-infiltrating lymphocytes in triple-negative breast cancer. JAMA. 2024;331(13):1135–44.

pubmed: 38563834 doi: 10.1001/jama.2024.3056

Krieg C, Nowicka M, Guglietta S, et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018;24(2):144–53.

pubmed: 29309059 doi: 10.1038/nm.4466

Wistuba-Hamprecht K, Martens A, Weide B, et al. Establishing high dimensional immune signatures from peripheral blood via mass cytometry in a discovery cohort of stage IV melanoma patients. J Immunol. 2017;198(2):927–36.

pubmed: 27986910 doi: 10.4049/jimmunol.1600875

Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, et al. Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancerimmunologic changes with chemotherapy in TNBC. Clin Cancer Res. 2020;26(21):5668–81.

pubmed: 32826327 pmcid: 7642197 doi: 10.1158/1078-0432.CCR-19-3685

Huebner H, Rübner M, Schneeweiss A, et al. RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial. American Society of Clinical Oncology; 2023.

doi: 10.1200/JCO.2023.41.16_suppl.1011

Spitzer MH, Nolan GP. Mass cytometry: single cells, many features. Cell. 2016;165(4):780–91.

pubmed: 27153492 pmcid: 4860251 doi: 10.1016/j.cell.2016.04.019

Goetz MP, Kalari KR, Suman VJ, et al. Tumor sequencing and patient-derived xenografts in the neoadjuvant treatment of breast cancer. JNCI J Natl Cancer Inst. 2017;109(7):djw306.

pubmed: 28376176 doi: 10.1093/jnci/djw306

Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47.

pubmed: 21709140 pmcid: 3144634 doi: 10.1093/annonc/mdr304

Symmans WF, Wei C, Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35(10):1049.

pubmed: 28135148 pmcid: 5455352 doi: 10.1200/JCO.2015.63.1010

Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149–60.

pubmed: 34902335 doi: 10.1016/S1470-2045(21)00589-1

Rybakowska P, Van Gassen S, Quintelier K, et al. Data processing workflow for large-scale immune monitoring studies by mass cytometry. Comput Struct Biotechnol J. 2021;19:3160–75.

pubmed: 34141137 pmcid: 8188119 doi: 10.1016/j.csbj.2021.05.032

Sahaf B, Pichavant M, Lee BH, et al. Immune profiling mass cytometry assay harmonization: multicenter experience from CIMAC-CIDC. Clin Cancer Res. 2021;27(18):5062–71.

pubmed: 34266889 pmcid: 8448982 doi: 10.1158/1078-0432.CCR-21-2052

Finck R, Simonds EF, Jager A, et al. Normalization of mass cytometry data with bead standards. Cytometry A. 2013;83(5):483–94. https://doi.org/10.1002/cyto.a.22271[publishedOnlineFirst:20130319] .

doi: 10.1002/cyto.a.22271[publishedOnlineFirst:20130319] pubmed: 23512433 pmcid: 3688049

Bagwell CB, Inokuma M, Hunsberger B, et al. Automated data cleanup for mass cytometry. Cytometry A. 2020;97(2):184–98.

pubmed: 31737997 doi: 10.1002/cyto.a.23926

Van Gassen S, Callebaut B, Van Helden MJ, et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A. 2015;87(7):636–45.

pubmed: 25573116 doi: 10.1002/cyto.a.22625

McInnes L, Healy J, Melville J. Umap: uniform manifold approximation and projection for dimension reduction. arXiv preprint https://arxiv.org/abs/1802.03426 (2018).

Leon-Ferre RA, Jonas SF, Salgado R, et al. Abstract PD9-05: stromal tumor-infiltrating lymphocytes identify early-stage triple-negative breast cancer patients with favorable outcomes at 10-year follow-up in the absence of systemic therapy: a pooled analysis of 1835 patients. Cancer Res. 2023;83(5):PD9-05.

doi: 10.1158/1538-7445.SABCS22-PD9-05

Verghese G, Li M, Liu F, et al. Multiscale deep learning framework captures systemic immune features in lymph nodes predictive of triple negative breast cancer outcome in large-scale studies. J Pathol. 2023;260(4):376–89.

pubmed: 37230111 pmcid: 10720675 doi: 10.1002/path.6088

Liu F, Hardiman T, Wu K, et al. Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication. NPJ Breast Cancer. 2021;7(1):86.

pubmed: 34226563 pmcid: 8257702 doi: 10.1038/s41523-021-00292-y

Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16(7):447–62.

pubmed: 27339708 doi: 10.1038/nrc.2016.54

Condamine T, Mastio J, Gabrilovich DI. Transcriptional regulation of myeloid-derived suppressor cells. J Leucoc Biol. 2015;98(6):913–22.

doi: 10.1189/jlb.4RI0515-204R

Gubin MM, Esaulova E, Ward JP, et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell. 2018;175(4):1014–30.

pubmed: 30343900 pmcid: 6501221 doi: 10.1016/j.cell.2018.09.030

Zhu Y, Herndon JM, Sojka DK, et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity. 2017;47(2):323–38.

pubmed: 28813661 pmcid: 5578409 doi: 10.1016/j.immuni.2017.07.014

Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–74.

pubmed: 19197294 pmcid: 2828349 doi: 10.1038/nri2506

Zhang Y, Chen H, Mo H, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021;39(12):1578–93.

pubmed: 34653365 doi: 10.1016/j.ccell.2021.09.010

Ye J-h, Wang X-h, Shi J-j, et al. Tumor-associated macrophages are associated with response to neoadjuvant chemotherapy and poor outcomes in patients with triple-negative breast cancer. J Cancer. 2021;12(10):2886.

pubmed: 33854589 pmcid: 8040876 doi: 10.7150/jca.47566

Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166(1):678–89.

pubmed: 11123353 doi: 10.4049/jimmunol.166.1.678

Azizi E, Carr AJ, Plitas G, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174(5):1293–308.

pubmed: 29961579 pmcid: 6348010 doi: 10.1016/j.cell.2018.05.060

Lambrechts D, Wauters E, Boeckx B, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 2018;24(8):1277–89.

pubmed: 29988129 doi: 10.1038/s41591-018-0096-5

Yam C, Yen E-Y, Chang JT, et al. Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer. Clin Cancer Res. 2021;27(19):5365–75.

pubmed: 34253579 pmcid: 8752638 doi: 10.1158/1078-0432.CCR-21-0144

Takahashi H, Sakakura K, Ida S, et al. Circulating naïve and effector memory T cells correlate with prognosis in head and neck squamous cell carcinoma. Cancer Sci. 2022;113(1):53.

pubmed: 34751489 doi: 10.1111/cas.15195

Zhao X, Zhang Y, Gao Z, et al. Prognostic value of peripheral naive CD8+ T cells in oligometastatic non-small-cell lung cancer. Future Oncol. 2021;18(1):55–65.

pubmed: 34608815 doi: 10.2217/fon-2021-0728

Tesch ME, Guzman Arocho YD, Collins LC, et al. Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics and prognosis in young women with HR+/HER2-breast cancer (BC). American Society of Clinical Oncology; 2023.

doi: 10.1200/JCO.2023.41.16_suppl.505

Hinrichs CS, Borman ZA, Gattinoni L, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood J Am Soc Hematol. 2011;117(3):808–14.

Arana Echarri A, Struszczak L, Beresford M, et al. Immune cell status, cardiorespiratory fitness and body composition among breast cancer survivors and healthy women: a cross sectional study. Front Physiol. 2023;14:879.

doi: 10.3389/fphys.2023.1107070

Fernandez-Martinez A, Pascual T, Singh B, et al. Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials. JAMA Oncol. 2023;9(4):490–9.

pubmed: 36602784 pmcid: 9857319 doi: 10.1001/jamaoncol.2022.6288

Taylor C, Hershman D, Shah N, et al. Augmented HER-2–specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res. 2007;13(17):5133–43.

pubmed: 17785568 doi: 10.1158/1078-0432.CCR-07-0507

Knutson KL, Clynes R, Shreeder B, et al. Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain. Can Res. 2016;76(13):3702–10.

doi: 10.1158/0008-5472.CAN-15-3091

Fristedt R, Borg D, Hedner C, et al. Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. J Gastrointest Oncol. 2016;7(6):848.

pubmed: 28078109 pmcid: 5177573 doi: 10.21037/jgo.2016.11.07

Hennequin A, Derangere V, Boidot R, et al. Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. Oncoimmunology. 2016;5(2):e1054598.

pubmed: 27057426 doi: 10.1080/2162402X.2015.1054598

Berntsson J, Nodin B, Eberhard J, et al. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer. 2016;139(5):1129–39.

pubmed: 27074317 doi: 10.1002/ijc.30138

Bosisio FM, Wilmott JS, Volders N, et al. Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Mod Pathol. 2016;29(4):347–58.

pubmed: 26867783 doi: 10.1038/modpathol.2016.28

Milne K, Köbel M, Kalloger SE, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE. 2009;4(7):e6412.

pubmed: 19641607 pmcid: 2712762 doi: 10.1371/journal.pone.0006412

Lohr M, Edlund K, Botling J, et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett. 2013;333(2):222–8.

pubmed: 23370224 doi: 10.1016/j.canlet.2013.01.036

Tsuda B, Miyamoto A, Yokoyama K, et al. B-cell populations are expanded in breast cancer patients compared with healthy controls. Breast Cancer. 2018;25(3):284–91.

pubmed: 29204848 doi: 10.1007/s12282-017-0824-6

Kuroda H, Jamiyan T, Yamaguchi R, et al. Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer. Breast Cancer. 2021;28:904–14.

pubmed: 33629216 doi: 10.1007/s12282-021-01227-y

Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21.

pubmed: 32101663 doi: 10.1056/NEJMoa1910549